Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)

Sector: Healthcare Industry: Biotechnology CIK: 0001515673
P/B 1,640.82
P/E -6.11
P/S 5.62
Market Cap 3.54 Bn
ROIC (Qtr) -58.19
Div Yield % 0.00
Rev 1y % (Qtr) 14.65
Total Debt (Qtr) 863.11 Mn
Debt/Equity (Qtr) 399.77

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 202.51M provide 2.61x coverage of short-term debt 77.69M, demonstrating strong liquidity position and minimal refinancing risk.
  • Robust tangible asset base of 973.10M provides 3.21x coverage of working capital 303.18M, indicating strong operational backing.
  • Tangible assets of 973.10M provide robust 4.39x coverage of other current liabilities 221.76M, indicating strong asset backing.
  • Cash reserves of 202.51M provide solid 4.15x coverage of other non-current liabilities 48.84M, indicating strong liquidity.
  • Cash reserves of 202.51M exceed inventory value of 52.20M by 3.88x, indicating strong liquidity and inventory management.

Cons

  • Operating cash flow of (445.67M) barely covers its investment activities of 410.98M, with a coverage ratio of -1.08, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of 410.98M provide weak support for R&D spending of 734.49M, which is 0.56x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (445.67M) shows concerning coverage of stock compensation expenses of 155.88M, with a -2.86 ratio indicating potential earnings quality issues.
  • High receivables of 112.54M relative to inventory of 52.20M (2.16 ratio) suggests aggressive credit terms or collection difficulties, potentially masking revenue quality issues.
  • Free cash flow of (451.39M) provides weak coverage of capital expenditures of 5.72M, with a -78.97 ratio suggesting additional external financing needs for growth initiatives.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 3.57 12.31
EV to Cash from Ops. -9.53 23.25
EV to Debt 4.92 738.44
EV to EBIT -7.37 -9.16
EV to EBITDA -8.29 6.95
EV to Free Cash Flow [EV/FCF] -9.41 21.90
EV to Market Cap 1.20 65.67
EV to Revenue 6.74 227.32
Price to Book Value [P/B] 1,640.82 22.34
Price to Earnings [P/E] -6.11 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 32.25 -27.13
Cash and Equivalents Growth (1y) % 34.45 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -3.73 -46.93
EBITDA Growth (1y) % -2.25 -1.68
EBIT Growth (1y) % -2.79 -56.45
EBT Growth (1y) % -2.79 -12.70
EPS Growth (1y) % 7.20 -28.31
FCF Growth (1y) % -5.71 -31.90
Gross Profit Growth (1y) % 18.45 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.53 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 0.60 3.85
Current Ratio 1.89 7.27
Debt to Equity Ratio 399.77 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % -85.90 -18,234.31
EBIT Margin % -91.46 -18,580.80
EBT Margin % -91.46 -19,488.74
Gross Margin % 84.70 -7.59
Net Profit Margin % -91.90 -19,439.22